User profiles for Douglas W. Blayney
Douglas BlayneyProfessor of Medicine (Oncology), emeritus Verified email at stanford.edu Cited by 17423 |
American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options
…, DS Wollins, C Tyne, DW Blayney… - Journal of Clinical …, 2015 - ascopubs.org
Health care costs in the United States present a major challenge to the national economic
well being. The Centers for Medicare and Medicaid Services (CMS) has projected that US …
well being. The Centers for Medicare and Medicaid Services (CMS) has projected that US …
[PDF][PDF] American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology
…, TJ Smith, D Raghavan, DW Blayney… - J Clin …, 2012 - canceradvocacy.org
Advancements in the prevention, diagnosis, and treatment of cancer have contributed to
improved survival, better quality of life, and declining death rates in the United States. With …
improved survival, better quality of life, and declining death rates in the United States. With …
Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network
…, RL Theriault, SB Edge, YN Wong, DW Blayney… - Cancer, 2012 - Wiley Online Library
BACKGROUND: The objective of this study was to describe clinicopathologic features,
patterns of recurrence, and survival according to breast cancer subtype with a focus on triple‐…
patterns of recurrence, and survival according to breast cancer subtype with a focus on triple‐…
[PDF][PDF] Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received
…, DS Wollins, DW Blayney… - Journal of Clinical …, 2016 - populationmedicine.org
The mission of American Society of Clinical Oncology (ASCO) is to conquer cancer through
research, education, and promotion of the highest quality patient care. Toward fulfillment of …
research, education, and promotion of the highest quality patient care. Toward fulfillment of …
[PDF][PDF] Subtype-dependent relationship between young age at diagnosis and breast cancer survival
…, YN Wong, SB Edge, RL Theriault, DW Blayney… - Journal of Clinical …, 2016 - cinj.org
Purpose Young women are at increased risk for developing more aggressive subtypes of
breast cancer. Although previous studies have shown a higher risk of breast cancer recurrence …
breast cancer. Although previous studies have shown a higher risk of breast cancer recurrence …
[HTML][HTML] Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors
…, SB Edge, RL Theriault, DW Blayney… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
… Douglas W. Blayney … Cleator S, Heller W, Coombes RC. Triple-negative breast cancer:
Therapeutic options. Lancet Oncol. …
Therapeutic options. Lancet Oncol. …
Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center
…, CW Ross, MS Kaminski, DW Blayney - Journal of Clinical …, 2009 - ascopubs.org
Purpose We studied the incidence, risk factors, treatment, and outcomes of post-transplantation
lymphoproliferative disorder (PTLD) that occurred at the University of Michigan since …
lymphoproliferative disorder (PTLD) that occurred at the University of Michigan since …
Neurotoxic effects of anthracycline-vs nonanthracycline-based chemotherapy on cognition in breast cancer survivors
SR Kesler, DW Blayney - JAMA oncology, 2016 - jamanetwork.com
Importance Chemotherapy exposure is a known risk factor for cancer-related cognitive
impairments. Anthracycline-based regimens are commonly used chemotherapies that have been …
impairments. Anthracycline-based regimens are commonly used chemotherapies that have been …
Myeloid growth factors, version 2.2017, NCCN clinical practice guidelines in oncology
…, PS Becker, JO Armitage, DW Blayney… - Journal of the National …, 2017 - jnccn.org
Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive
chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN …
chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN …
The effect of age on delay in diagnosis and stage of breast cancer
…, YN Wong, SB Edge, RL Theriault, DW Blayney… - The …, 2012 - academic.oup.com
Background. Young women with breast cancer are more likely to present with more advanced
disease and are more likely to die as a result of breast cancer than their older counterparts…
disease and are more likely to die as a result of breast cancer than their older counterparts…